Good MorningEquities rebounded again on Thursday but there is a growing list of companies giving reasons why the rally shouldn't be trusted. The key takeaways from earnings reports this weak are that near-term headwinds are growing because of the Ukrainian conflict and they may worsen as the war wears on. Not only is the conflict causing a spike in energy prices but it is also putting a strain on an already struggling supply chain. What this means for S&P 500 companies is a negative impact to the top and bottom line, declining expectations for revenue and earnings, and lower prices for the S&P 500 index.
Friday's market action will be driven by geopolitical sentiment and Fedspeak. There are at least 4 Fed members on the schedule to make remarks and each will be closely watched for clues about interest rates. Fed chief Jerome Powell surprised the market earlier in the week when he gave a more hawkish opinion of the inflation outlook than what was expected and now the market is pricing in a 50 basis point hike at the next FOMC meeting. Featured: FORGET 99% of The Stock Market (Legacy- ALL Campaigns) 
|
Politics | | | Global stock markets were mixed Friday after Western governments promised new sanctions on Russia and President Vladimir Putin tried to prop up Moscow's sinking ruble by threatening to require Europe to use it to pay for gas exports.
London and Shanghai declined while Tokyo gained and... Read the Full Story |
|
From Our PartnersMarkets are an absolute disaster.
With Russia's invasion of Ukraine, inflationary threats, a potential recession, and likely interest rate hikes on the way, investors are terrified. Plus, with oil prices now above $110 a barrel, there are concerns pump prices could substantially curb consumer spending.
And unfortunately, no one is quite sure what comes next.
Here are five ways to protect your portfolio right now. | | Click Here to Download the FREE Report |
|
Markets | | |
This might not be a question you were expecting to hear with regards to NIO (NYSE: NIO), whose shares are down almost 70% from last year’s all-time high, but it’s one worth asking. Because if one thing’s for sure, the Shanghai headquartered electric vehicle (EV) maker knows how t... Read the Full Story |
|
Markets | | |
There will always be a need for healthcare. Doctor visits, prescriptions, medical equipment, and of course, vaccines will remain fixtures in our society for decades to come.
This is what makes the defensive healthcare sector a good place to park funds for the long-term. Regardless of the ec... Read the Full Story |
|
From Our PartnersThere aren't enough semiconductor chips in the world to meet the skyrocketing demand.
But due to the global chip shortage...
These four companies are well-positioned to take advantage of this rapidly growing demand over the next 12 months and beyond. | | Click here to see the 4 stocks |
|
Politics | | | The United States and European Union on Friday announced a new partnership to reduce the continent's reliance on Russian energy, a step top officials characterized as the start of a years-long initiative to further isolate Moscow after its invasion of Ukraine.
U.S. President Joe Bide... Read the Full Story |
|
Politics | | | MOSCOW — Russian Foreign Minister Sergey Lavrov says Russia is facing total war declared by the West.
Lavrov said at a meeting on Friday that “a real hybrid war, total war was declared on us.” He said the goal was “to destroy, break, annihilate, strangle the Russian economy, and Russi... Read the Full Story |
|
From Our PartnersWhat if you could IGNORE 99% of the stock market and still make 373% gains in 8 days? | | | | Continue Reading |
|
Politics | | | Spain’s government and the country’s main trucking federations have reached an agreement on financial help for an industry that is hurting from high gas prices, but self-employed truckers said Friday they would continue a 12-day strike.
Russia’s war in Ukraine has helped drive gas pri... Read the Full Story |
|
Politics | | | KYIV, Ukraine — The government of the Ukrainian city of Mariupol says 300 people died in a Russian airstrike on March 16 on a theater being used as a bomb shelter.
The post Friday on the city government Telegram channel cited eyewitnesses for the toll of “about 300.” It was not immed... Read the Full Story |
|
Markets | | | What to do when eastern Europe suddenly erupts into violence? Griping about the cost of gasoline (has anyone else shifted to filling up when the tank is half full?) has its cathartic moments, but it's also important to remember that whole countries are living in fear right now.
Even so, beyond dona... Read the Full Story |
|
Markets | | | 3D printing and digital manufacturing solutions provider 3D Systems (NASDAQ: DDD) stock has sold-off over (-60%) from its pandemic high of $56.50. The maker of 3D printing systems has seen growing mainstream adaption of the technology from the aerospace, automotive, electronics, manufacturing, indus... Read the Full Story |
|
Markets | | | Despite a bearish earnings report, OLLI stock is showing signs it may be getting ready to reverse its bearish trend. But with short interest remaining high, opportunistic investors should wait for confirmation of a reversal before buying the company’s shares Read the Full Story |
|
Friday's Early Bird Stock Of The Day Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. | | View Today's Stock Pick |
|
